Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and
temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast
(MN-166) and TMZ combination treatment for 1 cycle (28 days); determine dosage in
dose-finding study. Part 2 will evaluate efficacy of fixed-dose MN-166 (ibudilast) and TMZ
combination treatment for 6 cycles (~6 months) until disease progression, unacceptable
tolerability and/or toxicity or loss of life.